Elizabeth B. Hirsch

发表

The Activity of Antimicrobial Surfaces Varies by Testing Protocol Utilized

M. Campos, P. Zucchi, A. Phung, 2016, PloS one.

Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.

Vincent H Tam, V. Tam, Elizabeth B. Hirsch, 2010, The Journal of antimicrobial chemotherapy.

Integrated microfluidic platform for rapid antimicrobial susceptibility testing and bacterial growth analysis using bead-based biosensor via fluorescence imaging

Pooja Sabhachandani, James E. Kirby, Tania Konry, 2017, Microchimica Acta.

Duodenoscope hang time does not correlate with risk of bacterial contamination

G. Snyder, Elizabeth B. Hirsch, S. Wright, 2017, American journal of infection control.

Nasal methicillin-resistant Staphylococcus aureus screening in patients with pneumonia: A powerful antimicrobial stewardship tool.

G. Snyder, M. Mahoney, Elizabeth B. Hirsch, 2017, American journal of infection control.

The antimicrobial peptide DGL13K is active against drug-resistant gram-negative bacteria and sub-inhibitory concentrations stimulate bacterial growth without causing resistance

S. Gorr, Elizabeth B. Hirsch, Hunter V Brigman, 2020, bioRxiv.

Surface Microbiology of the iPad Tablet Computer and the Potential to Serve as a Fomite in Both Inpatient Practice Settings as Well as Outside of the Hospital Environment

Jason W. Lancaster, Steven N. Leonard, Elizabeth B. Hirsch, 2014, PloS one.

In a Pinch: Cefiderocol for CRAB Infections

Elizabeth B. Hirsch, E. Heil, S. Karaba, 2022, Antimicrobial agents and chemotherapy.

Differences in Fosfomycin Resistance Mechanisms between Pseudomonas aeruginosa and Enterobacterales

C. Landersdorfer, Phillip J. Bergen, Elizabeth B. Hirsch, 2021, Antimicrobial agents and chemotherapy.

Adenosine Triphosphate Quantification Correlates Poorly with Microbial Contamination of Duodenoscopes

G. Snyder, Elizabeth B. Hirsch, S. Wright, 2017, Infection Control & Hospital Epidemiology.

Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.

G. Snyder, M. Mahoney, Elizabeth B. Hirsch, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Atypical Antipsychotic Quetiapine Promotes Multiple Antibiotic Resistance in Escherichia coli

M. Federle, Stephanie A. Flowers, Yasuhiro Kyono, 2022, Journal of bacteriology.

Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors

M. Nikolaou, V. Tam, Pratik Bhagunde, 2012, Antimicrobial Agents and Chemotherapy.

Tolerance to antibiotics affects response

Elizabeth B. Hirsch, A. Berti, 2020, Science.

Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity.

P. Beuning, K. Takrouri, P. Zucchi, 2017, Bioorganic & medicinal chemistry letters.

Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

V. Tam, J. Altshuler, Elizabeth B. Hirsch, 2015, International journal of antimicrobial agents.

A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections

Jason C. Gallagher, Daohai Yu, Christopher M. Bland, 2021, Open forum infectious diseases.

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centers.

G. Eliopoulos, R. Hunter, P. Zucchi, 2020, Journal of global antimicrobial resistance.

Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model

C. Landersdorfer, Phillip J. Bergen, A. Peleg, 2018, The Journal of antimicrobial chemotherapy.

Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes

M. D. Hogan, M. Hogan, M. Mahoney, 2016, Chemotherapy.

Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

C. Landersdorfer, Phillip J. Bergen, C. Kirkpatrick, 2016, The Journal of antimicrobial chemotherapy.

Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics

G. Eliopoulos, J. Kirby, P. Zucchi, 2016, Antimicrobial Agents and Chemotherapy.

Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia

D. Thompson, M. Mahoney, Elizabeth B. Hirsch, 2015, PloS one.

Progress against Escherichia coli with the Oxazolidinone Class of Antibacterials: Test Case for a General Approach To Improving Whole-Cell Gram-Negative Activity.

P. Beuning, K. Takrouri, P. Zucchi, 2016, ACS infectious diseases.

Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

V. Tam, Elizabeth B. Hirsch, 2010, Expert review of pharmacoeconomics & outcomes research.

Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.

M. Mahoney, Elizabeth B. Hirsch, Jordan L. Liscio, 2015, International journal of antimicrobial agents.

Assessment of Mortality Stratified by Meropenem MIC in Patients with Enterobacteriaceae Bacteremia: A Patient-level Analysis of Published Data.

Elizabeth B. Hirsch, J. Esterly, T. Patel, 2019, International journal of antimicrobial agents.

Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.

J. Kirby, P. Zucchi, Elizabeth B. Hirsch, 2017, Diagnostic microbiology and infectious disease.

Volatile metabolic diversity of Klebsiella pneumoniae in nutrient-replete conditions

Elizabeth B. Hirsch, F. Franchina, C. Rees, 2017, Metabolomics.

In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria

V. Tam, M. Motyl, Elizabeth B. Hirsch, 2012, Antimicrobial Agents and Chemotherapy.

Detection of high-risk carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates using volatile molecular profiles

Mavra Nasir, A. Smolinska, Y. Doi, 2018, Scientific Reports.

Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

V. Tam, Elizabeth B. Hirsch, Manisha Singh, 2013, The Journal of infectious diseases.

Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical Pseudomonas aeruginosa Isolates

C. Landersdorfer, Elizabeth B. Hirsch, C. Emery, 2020, Journal of Clinical Microbiology.

Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections

G. Snyder, M. Mahoney, Elizabeth B. Hirsch, 2019, Chemotherapy.

A model to predict mortality following Pseudomonas aeruginosa bacteremia.

Michael L. Johnson, V. Tam, J. Caeiro, 2012, Diagnostic microbiology and infectious disease.

Minnesota One Health Antibiotic Stewardship Collaborative: A Reproducible Approach to Facilitate Antimicrobial Stewardship Progress

R. Lynfield, Elizabeth B. Hirsch, A. Beaudoin, 2022, Open forum infectious diseases.

The Atypical Antipsychotic Quetiapine Induces Multiple Antibiotic Resistance in Escherichia coli

M. Federle, Stephanie A. Flowers, Yasuhiro Kyono, 2021, bioRxiv.

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

M. Mahoney, Elizabeth B. Hirsch, S. Giancola, 2016, Therapeutics and clinical risk management.

Significant publications on infectious diseases pharmacotherapy in 2010.

Elizabeth B. Hirsch, T. Tran, D. Shah, 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Significant publications on infectious diseases pharmacotherapy in 2009.

V. Tam, K. Garey, Elizabeth B. Hirsch, 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Randomized Comparison of 3 High-Level Disinfection and Sterilization Procedures for Duodenoscopes.

Roger B. Davis, R. Chuttani, G. Snyder, 2017, Gastroenterology.

Evaluation of a daptomycin dose-optimization protocol.

V. Tam, J. Weston, K. Garey, 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Significant publications on infectious diseases pharmacotherapy in 2008.

V. Tam, Elizabeth B. Hirsch, K. Kuper, 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.

G. Eliopoulos, J. Kirby, P. Zucchi, 2015, International journal of antimicrobial agents.

Brighter horizons: The necessity of concentrated sponsorship targeted toward minoritized student pharmacists.

Jason Mordino, Elizabeth B. Hirsch, J. Abdul‐Mutakabbir, 2022, Journal of the American Pharmacists Association.

Academic Activism: An Avenue to Action.

Elizabeth B. Hirsch, J. Abdul‐Mutakabbir, Michelle A Fravel, 2023, American journal of pharmaceutical education.

Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists

E. Wenzler, A. Schuetz, Elizabeth B. Hirsch, 2023, Pharmacotherapy.

An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.

V. Tam, P. Zucchi, Elizabeth B. Hirsch, 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

A call to action: A need for initiatives that increase equitable access to COVID-19 therapeutics

T. Swartz, Jason Mordino, Elizabeth B. Hirsch, 2022, The Lancet Regional Health - Americas.

Volatile metabolic diversity of Klebsiella pneumoniae in nutrient-replete conditions

Elizabeth B. Hirsch, F. Franchina, C. Rees, 2017, Metabolomics.

Opportunities for antibiotic stewardship in emergency department or hospitalized patients with asymptomatic bacteriuria: identifying risk factors for antibiotic treatment

Elizabeth B. Hirsch, Brian R. Raux, M. Bixby, 2022, Antimicrobial Stewardship and Healthcare Epidemiology.

Predictors of adverse safety events and unscheduled care among an outpatient parenteral antimicrobial therapy (OPAT) patient cohort

S. Kline, Elizabeth B. Hirsch, Michael D. Evans, 2023, Therapeutic advances in infectious disease.

Correlation of Hospital Carbapenem Consumption and Resistance Trends in Selected Gram-Negative Bacteria

V. Tam, L. Gentry, Elizabeth B. Hirsch, 2012, The Annals of pharmacotherapy.

Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia.

V. Tam, Elizabeth B. Hirsch, T. Patel, 2016, Diagnostic microbiology and infectious disease.

Three Degrees of Carnapian Tolerance

Elizabeth B. Hirsch, 2016 .

Emergence of KPC-producing Klebsiella pneumoniae in Texas.

V. Tam, J. Caeiro, Elizabeth B. Hirsch, 2011, Diagnostic microbiology and infectious disease.

Detection of high-risk carbapenem-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates using volatile molecular profiles

Mavra Nasir, A. Smolinska, Y. Doi, 2018, Scientific Reports.

Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.

M. Mahoney, Elizabeth B. Hirsch, Jordan L. Liscio, 2015, International journal of antimicrobial agents.